phpvKcHXR.jpg

[ad_1]

The Sports Arbitral Tribunal confirmed on Thursday the heavy suspension of the French wrestler, deprived of the Tokyo Olympics where he had a medal chance in his category.

France Télévisions – Sport writing

Published


Updated


Reading time: 1min

The facade of the Sports Arbitral Tribunal, in Lausanne (Switzerland), December 17, 2020. (Fabrice Coffrini / AFP)

The facade of the Sports Arbitral Tribunal, in Lausanne (Switzerland), on December 17, 2020. (Fabrice Coffrini / AFP)

France has just officially lost one of its medal chances at the Tokyo Olympic Games. THE Sports arbitration tribunal (TAS) confirmed Thursday, May 6, The four years of suspension for doping of the French wrestler Zelimkhan Khadjiev (in PDF), positively controlled in September 2019 in Vastarel, a medication supposed to relieve the angina of chest and whose active ingredient, trimetazidine, has been prohibited since 2014 by the World Anti -Doping Agency (AMA).

The 26-year-old wrestler, a double vice-champion of Europe (-74 kg), had himself acknowledged having bought these tablets near the National Sports Institute (INSEP) in Vincennes, on the advice of a coach, to appease leg pain.

“The instruction made it possible to demonstrate” that this active ingredient “was clearly indicated on the box as well as in the medication manual”and the wrestler would have “easily” Powering that he was on the list of doping products, said the job in a press release.

“By not carrying out basic research on the substance in question”Zelimkhan Khadjiev “Obviously ignored” The risk of violating anti-doping regulations, continues the arbitral jurisdiction.

The Nice of Chechen origin did not obtain a reduction in the suspension period, pronounced in July 2020 by the International Federation of struggle, failing to have demonstrated that this violation was not “Not intentional”.

Twice silver medalist at the European championships, Khadjiev participated in the Rio Olympic Games in 2016 where he had finished in an honorable 8th place.



[ad_2]

Leave a Reply

Your email address will not be published. Required fields are marked *